Regenxbio (RGNX) Other Operating Expenses (2014 - 2026)
Regenxbio (RGNX) posted quarterly Other Operating Expenses of -$72.4 million for Q4 2025, down 3466.99% year-over-year from $2.2 million in Q4 2024, and down 1350.85% quarter-over-quarter from $5.8 million in Q3 2025.
Regenxbio (RGNX) Other Operating Expenses (2014 - 2026) Analysis & Trends
Regenxbio's Other Operating Expenses history runs 12 years deep, the most recent figure standing at -$72.4 million for Q4 2025.
- In Q4 2025, Other Operating Expenses fell 3466.99% year-over-year to -$72.4 million; the TTM figure through Dec 2025 stood at -$134.9 million (down 527.89% YoY), while the FY2025 annual figure was -$278.3 million, down 982.58% from the prior year.
- Other Operating Expenses for Q4 2025 stood at -$72.4 million, down from $5.8 million in the prior quarter.
- The five-year high for Other Operating Expenses was $38.0 million in Q1 2022, with the low at -$422.8 million in Q4 2022.
- The 5-year median for Other Operating Expenses is $7.9 million (2023), against an average of -$20.1 million.
- The sharpest annual moves came in 2021 and 2025: Other Operating Expenses soared 20008.0% in 2021, then sank 3466.99% in 2025.
- Regenxbio's Other Operating Expenses stood at $15.0 million in 2021, then plunged by 2910.99% to -$422.8 million in 2022, then soared by 86.33% to -$57.8 million in 2023, then surged by 103.72% to $2.2 million in 2024, then tumbled by 3466.99% to -$72.4 million in 2025.
- Business Quant data shows RGNX's Other Operating Expenses at -$72.4 million in Q4 2025, $5.8 million in Q3 2025, and -$71.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Mn |
| Dec 31, 2025 | -72.42 Mn |
| Sep 30, 2025 | 5.79 Mn |
| Jun 30, 2025 | -71.75 Mn |
| Mar 31, 2025 | 3.45 Mn |
| Dec 31, 2024 | 2.15 Mn |
| Sep 30, 2024 | 12.42 Mn |
| Jun 30, 2024 | 10.61 Mn |
| Mar 31, 2024 | 6.35 Mn |
| Dec 31, 2023 | -57.78 Mn |
| Sep 30, 2023 | 12.61 Mn |
| Jun 30, 2023 | 9.50 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | -422.80 Mn |
| Sep 30, 2022 | 34.02 Mn |
| Jun 30, 2022 | 33.78 Mn |
| Mar 31, 2022 | 38.04 Mn |
| Dec 31, 2021 | 15.04 Mn |
| Sep 30, 2021 | 19.24 Mn |
| Jun 30, 2021 | 9.95 Mn |